|
Market Closed -
Nasdaq Stockholm
17:00:00 17/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 3.370 SEK | +1.20% |
|
-2.03% | +129.25% |
| 07-23 | Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development | CI |
| 06-26 | Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange | FW |
Company Valuation: Sprint Bioscience AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 191.1 | 22.03 | 121.1 | 110.5 | 155.1 | 351.4 | - |
| Change | - | -88.47% | 449.78% | -8.82% | 40.43% | 126.53% | - |
| Enterprise Value (EV) | 120.4 | -7.459 | 71.2 | 85.4 | 155.1 | 351.4 | 351.4 |
| Change | - | -106.19% | 1,054.57% | 19.94% | 81.63% | 126.53% | 0% |
| P/E | -5.64x | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.44x | 265x | 2.4x | 1.68x | 0.93x | 4.14x | 2.27x |
| EV / Revenue | 0x | -0x | 0x | 0x | 0x | 4.14x | 2.27x |
| EV / EBITDA | -0x | 0x | -0x | -0x | 0x | 11x | 3.63x |
| EV / EBIT | -0x | 0x | -0x | -0x | 0x | 11.4x | 3.67x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.85 | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 35.11 | 0.083 | 50.48 | 65.64 | 167.2 | 84.8 | 155 |
| EBITDA 1 | -25.04 | -60.12 | -0.398 | -18.71 | 98.36 | 31.8 | 96.7 |
| EBIT 1 | -25.63 | -60.74 | -0.845 | -19.67 | 97.29 | 30.7 | 95.7 |
| Net income | -25.08 | - | - | - | - | - | - |
| Net Debt | -70.64 | -29.49 | -49.93 | -25.06 | - | - | - |
| Reference price 2 | 4.795 | 0.553 | 1.735 | 1.582 | 1.470 | 3.330 | 3.330 |
| Nbr of stocks (in thousands) | 39,844 | 39,844 | 69,820 | 69,820 | 105,516 | 105,516 | - |
| Announcement Date | 16/02/22 | 15/02/23 | 14/02/24 | 12/02/25 | 11/02/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 36.95M | |
| 20.97x | 7.34x | 14.96x | 1.41% | 70.07B | |
| 30.34x | 7.64x | 23.38x | 0.05% | 52.87B | |
| -78.21x | 14.61x | -74.55x | -.--% | 27.02B | |
| 29.96x | 5.86x | 15.52x | -.--% | 23.61B | |
| -14.6x | 5.15x | -6.71x | -.--% | 23.38B | |
| 56.69x | 21.05x | 42.62x | 0.06% | 19.43B | |
| 25.59x | 4.85x | 16.27x | -.--% | 18.75B | |
| -802.92x | 37.67x | -14929.22x | -.--% | 15.85B | |
| 15.89x | 4.68x | 10.93x | -.--% | 12.7B | |
| Average | -79.59x | 12.09x | -1,654.09x | 0.17% | 26.37B | |
| Weighted average by Cap. | -36.49x | 10.35x | -890.98x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRINT Stock
- Valuation Sprint Bioscience AB
Select your edition
All financial news and data tailored to specific country editions
